{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:12:06Z","timestamp":1792181526635,"version":"4.4.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019345","name":"King Salman Center for Disability Research","doi-asserted-by":"publisher","award":["KSRG-2024-259"],"award-info":[{"award-number":["KSRG-2024-259"]}],"id":[{"id":"10.13039\/501100019345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110555","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:54:52Z","timestamp":1749156892000},"page":"110555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Berberine's paradox in Neurodegeneration: Therapeutic promise and safety challenges in Parkinson's disease"],"prefix":"10.1016","volume":"278","author":[{"given":"Sultan M.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-2343","authenticated-orcid":false,"given":"Mohamed N.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan F.","family":"Kadasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110555_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113839","article-title":"Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats","volume":"146","author":"Abdelaziz","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.pharep.2015.03.002","article-title":"Berberine and neurodegeneration: a review of literature","volume":"67","author":"Ahmed","year":"2015","journal-title":"Pharmacol. Reports"},{"key":"10.1016\/j.neuropharm.2025.110555_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102143","article-title":"Calprotectin in parkinsonian disease: anticipation and dedication","volume":"93","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2025.110555_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102075","article-title":"The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways","volume":"91","author":"Al-kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2025.110555_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18495","article-title":"The potential role of brain renin-angiotensin system in the neuropathology of Parkinson disease: friend, foe or turncoat?","volume":"28","author":"Al-Qahtani","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","article-title":"Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit","volume":"29","author":"Alharbi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00210-023-02726-9","article-title":"Irisin\/PGC-1\u03b1\/FNDC5 pathway in Parkinson's disease: truth under the throes","volume":"397","author":"Ali","year":"2024","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110555_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","article-title":"Role of brain liver X receptor in Parkinson's disease: hidden treasure and emerging opportunities","volume":"61","author":"Alnaaim","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113225","article-title":"Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress","volume":"152","author":"Alorabi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110555_bib10","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jcmm.17784","article-title":"NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: a narrative review and new perspective","volume":"27","author":"Alrouji","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/npr2.12445","article-title":"Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: a new perspective","author":"Alrouji","year":"2024","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1016\/j.neuropharm.2025.110555_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18412","article-title":"Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease","volume":"28","author":"Alrouji","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11010-023-04771-7","article-title":"Metformin role in Parkinson's disease: a double-sword effect","volume":"479","author":"Alrouji","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2025.110555_bib14","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1007\/s10072-023-06926-2","article-title":"The potential role of cholesterol in Parkinson's disease neuropathology: perpetrator or victim","volume":"44","author":"Alrouji","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib15","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s10787-022-01080-1","article-title":"The role of berberine in Covid-19: potential adjunct therapy","volume":"30","author":"Babalghith","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110555_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10059-013-2298-5","article-title":"Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1","volume":"35","author":"Bae","year":"2013","journal-title":"Mol. Cells"},{"key":"10.1016\/j.neuropharm.2025.110555_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10059-013-2298-5","article-title":"Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1","volume":"35","author":"Bae","year":"2013","journal-title":"Mol. Cells"},{"key":"10.1016\/j.neuropharm.2025.110555_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2021.09.006","article-title":"The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease","volume":"176","author":"Barone","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 pathway in Parkinson's disease: a faraway snapshot but so close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110555_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202500170","article-title":"Unraveling berberine's molecular mechanisms in neuroprotection against neurodegeneration","author":"Begh","year":"2025","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.neuropharm.2025.110555_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/15548627.2020.1728095","article-title":"AMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: different impact on \u03b2-amyloid clearance","volume":"17","author":"Benito-Cuesta","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2025.110555_bib22","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110555_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","article-title":"mTOR in brain physiology and pathologies","volume":"95","author":"Bockaert","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110555_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2025.110555_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1566524019666190315164120","article-title":"Berberine alleviates amyloid-beta pathogenesis via activating LKB1\/AMPK signaling in the brain of APP\/PS1 transgenic mice","volume":"19","author":"Cai","year":"2019","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fnagi.2020.00230","article-title":"Rapamycin, by inhibiting mTORC1 signaling, prevents the loss of striatal bidirectional synaptic plasticity in a rat model of L-DOPA-induced dyskinesia","volume":"12","author":"Calabrese","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","article-title":"Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of Parkinson's disease","volume":"37","author":"Cao","year":"2022","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.biopha.2017.08.040","article-title":"Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of Streptozotocin induced diabetic rats","volume":"95","author":"Chandirasegaran","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110555_bib30","doi-asserted-by":"crossref","DOI":"10.1055\/s-0036-1578659","article-title":"Berberine selectively inhibits human monoamine oxidase B: kinetics and mechanism of inhibition","volume":"82","author":"Chaurasiya","year":"2016","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01850-6","article-title":"From the regulatory mechanism of TFEB to its therapeutic implications","volume":"10","author":"Chen","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.neuropharm.2025.110555_bib32","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10495-014-0977-0","article-title":"Berberine reduces ischemia\/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats","volume":"19","author":"Chen","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.neuropharm.2025.110555_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109670","article-title":"Berberine mitigates cognitive decline in an Alzheimer's Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance","volume":"121","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110555_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.845591","article-title":"Berberine: a promising treatment for neurodegenerative diseases","volume":"13","author":"Cheng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2006.09.007","article-title":"Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK","author":"Cheng","year":"2006","journal-title":"Biochimica et Biophysica Acta - General Subjects"},{"key":"10.1016\/j.neuropharm.2025.110555_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-2-29","article-title":"The emerging role of autophagy in Parkinson's disease","volume":"2","author":"Cheung","year":"2009","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2025.110555_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-171296","article-title":"Targeting AMPK signaling as a neuroprotective strategy in Parkinson's disease","volume":"8","author":"Curry","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-171296","article-title":"Targeting AMPK signaling as a neuroprotective strategy in Parkinson's disease","volume":"8","author":"Curry","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-024-05419-5","article-title":"Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies","volume":"81","author":"Dai","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNR.0000000000001365","article-title":"Berberine alleviates rotenone-induced cytotoxicity by antioxidation and activation of PI3K\/Akt signaling pathway in SH-SY5Y cells","volume":"31","author":"Deng","year":"2020","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2025.110555_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNR.0000000000001365","article-title":"Berberine alleviates rotenone-induced cytotoxicity by antioxidation and activation of PI3K\/Akt signaling pathway in SH-SY5Y cells","volume":"31","author":"Deng","year":"2020","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2025.110555_bib42","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1039\/D1FO01360B","article-title":"Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice","volume":"12","author":"Deng","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.neuropharm.2025.110555_bib43","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1007\/s00018-018-2872-2","article-title":"Inhibition of protein misfolding and aggregation by natural phenolic compounds","volume":"75","author":"Dhouafli","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.18632\/aging.202181","article-title":"TRIM3 attenuates apoptosis in Parkinson's disease via activating PI3K\/AKT signal pathway","volume":"13","author":"Dong","year":"2021","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41401-020-0493-4","article-title":"Berberine improves intralipid-induced insulin resistance in murine","volume":"42","author":"Dong","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2025.110555_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105426","article-title":"Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation","volume":"157","author":"Drouyer","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib47","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.neurobiolaging.2012.02.016","article-title":"Berberine ameliorates \u03b2-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model","volume":"33","author":"Durairajan","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2025.110555_bib48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-Dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib49","article-title":"Natural products attenuate PI3K\/Akt\/mTOR signaling pathway: a promising strategy in regulating neurodegeneration","volume":"91","author":"Fakhri","year":"2021","journal-title":"Phytomedicine (Stuttg.)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2174\/1570159X16666180419141613","article-title":"Combating neurodegenerative diseases with the plant alkaloid berberine: molecular mechanisms and therapeutic potential","volume":"17","author":"Fan","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/abbs\/gmz156","article-title":"Glycogen synthase kinase-3 as a key regulator of cognitive function","volume":"52","author":"Fan","year":"2020","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.neuropharm.2025.110555_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.982145","article-title":"Research progress on the pharmacological effects of berberine targeting mitochondria","volume":"13","author":"Fang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib53","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/thno.30787","article-title":"Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics","volume":"9","author":"Feng","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.neuropharm.2025.110555_bib54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","article-title":"Identification of risk loci for Parkinson disease in asians and comparison of risk between asians and Europeans: a genome-wide association study","volume":"77","author":"Foo","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-020-00406-6","article-title":"Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism","volume":"12","author":"Frazier","year":"2021","journal-title":"Mol. Autism"},{"key":"10.1016\/j.neuropharm.2025.110555_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes11091045","article-title":"Regulation of MTORC2 signaling","volume":"11","author":"Fu","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.neuropharm.2025.110555_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00295","article-title":"Alpha-synuclein: from early synaptic dysfunction to neurodegeneration","volume":"9","author":"Ghiglieri","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib58","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.biopsych.2017.04.011","article-title":"\u03b2-Amyloid precursor protein intracellular domain controls mitochondrial function by modulating phosphatase and tensin homolog\u2013induced kinase 1 transcription in cells and in alzheimer mice models","volume":"83","author":"Goiran","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110555_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","article-title":"Glycogen synthase kinase-3 beta (GSK-3\u03b2) signaling: implications for Parkinson's disease","volume":"97","author":"Golpich","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228563","article-title":"A new twist in protein kinase b\/akt signaling: role of altered cancer cell metabolism in akt-mediated therapy resistance","volume":"21","author":"G\u00f6tting","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib61","article-title":"The PI3K-AKT pathway: a plausible therapeutic target in Parkinson's disease","volume":"129","author":"Goyal","year":"2022","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib62","first-page":"1","article-title":"Unraveling dysregulated cell signaling pathways, genetic and epigenetic mysteries of Parkinson's disease","author":"Hamidpour","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/nyas.12820","article-title":"Mitochondrial dysfunction and Parkinson disease: a Parkin\u2013AMPK alliance in neuroprotection","volume":"1350","author":"Hang","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jnr.22756","article-title":"Effects of berberine on hippocampal neuronal damage and matrix metalloproteinase-9 activity following transient global cerebral ischemia","volume":"90","author":"Hong","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejps.2012.03.004","article-title":"Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase\/Akt-dependent mechanism in NSC34 motor neuron-like cells","volume":"46","author":"Hsu","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib66","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.taap.2013.08.008","article-title":"Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth","volume":"272","author":"Hsu","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2011.11.014","article-title":"PI3K p55\u03b3 promoter activity enhancement is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion","volume":"674","author":"Hu","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib68","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/DDDT.S156920","article-title":"Vitexin protects dopaminergic neurons in mptp-induced Parkinson's disease through pi3k\/akt signaling pathway","volume":"12","author":"Hu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.neuropharm.2025.110555_bib69","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11064-014-1477-x","article-title":"Protein phosphatase 2A is involved in the tyrosine hydroxylase phosphorylation regulated by \u03b1-synuclein","volume":"40","author":"Hua","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.618787","article-title":"Berberine protects against NLRP3 inflammasome via ameliorating autophagic impairment in MPTP-induced Parkinson's disease model","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib71","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1080\/15548627.2021.1963630","article-title":"Endolysosome and autophagy dysfunction in Alzheimer disease","volume":"17","author":"Hung","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2025.110555_bib72","first-page":"199","article-title":"Berberine neuroprotection and antioxidant activity. Oxidative Stress Diet","author":"Imenshahidi","year":"2020","journal-title":"Antioxidants Neurol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib73","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ptr.6252","article-title":"Berberine and barberry (Berberis vulgaris): a clinical review","volume":"33","author":"Imenshahidi","year":"2019","journal-title":"Phyther. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib74","first-page":"1","article-title":"Non-motor symptoms of Parkinson's disease-insights from genetics","author":"Jer\u010di\u0107","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2025.110555_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2021.100854","article-title":"Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma","volume":"83","author":"Jhanwar-Uniyal","year":"2022","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.neuropharm.2025.110555_bib76","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/823201","article-title":"Molecular basis of inhibitory activities of berberine against pathogenic enzymes in Alzheimer's disease","volume":"2012","author":"Ji","year":"2012","journal-title":"Sci. World J."},{"key":"10.1016\/j.neuropharm.2025.110555_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113091","article-title":"Curcumin can improve Parkinson's disease via activating BDNF\/PI3k\/Akt signaling pathways","volume":"164","author":"Jin","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib78","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/alz.12607","article-title":"Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE \u025b2 for Alzheimer's disease","volume":"18","author":"Jun","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.neuropharm.2025.110555_bib79","first-page":"627","article-title":"6-hydroxydopamine-induced model of Parkinson's disease","volume":"2","author":"Kaczy\u0144ska","year":"2020","journal-title":"Genet. Neurol. Behav. Diet Park. Dis. Neurosci. Park. Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib80","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110555_bib81","first-page":"516","article-title":"Toxicology effects of berberis vulgaris (Barberry) and its active constituent, berberine: a review. Iran","volume":"20","author":"Kamrani Rad","year":"2017","journal-title":"J. Basic Med. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109088","article-title":"Parkinson's disease: exploring different animal model systems","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add0499","article-title":"Enhanced mTORC1 signaling and protein synthesis in pathologic \u03b1-synuclein cellular and animal models of Parkinson's disease","volume":"15","author":"Khan","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib84","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.fct.2010.01.033","article-title":"Acute toxicity of berberine and its correlation with the blood concentration in mice","volume":"48","author":"Kheir","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib86","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3892\/ijmm.2014.1656","article-title":"Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease","volume":"33","author":"Kim","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib87","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3892\/ijmm.2014.1656","article-title":"Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease","volume":"33","author":"Kim","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib88","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib89","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12035-021-02611-7","article-title":"Implications of phosphoinositide 3-kinase-akt (PI3K-akt) pathway in the pathogenesis of alzheimer's disease","volume":"59","author":"Kumar","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2010.09.038","article-title":"Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease","volume":"486","author":"Kwon","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110555_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107129","article-title":"Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury","volume":"9","author":"Kysenius","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110555_bib92","doi-asserted-by":"crossref","DOI":"10.1007\/s12017-016-8417-7","article-title":"mTOR signaling in Parkinson's disease","volume":"19","author":"Lan","year":"2017","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41419-024-06657-y","article-title":"Therapeutic role of PTEN in tissue regeneration for management of neurological disorders: stem cell behaviors to an in-depth review","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2019.10.025","article-title":"Deletion of glycogen synthase kinase-3\u03b2 in D2 receptor\u2013positive neurons ameliorates cognitive impairment via NMDA receptor\u2013dependent synaptic plasticity","volume":"87","author":"Li","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110555_bib95","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson's disease on behalf of Kings Parcog groupMDS Nonmotor study group","volume":"266","author":"Lim","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib96","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3233\/JPD-230376","article-title":"Parkinson's disease is predominantly a genetic disease","volume":"14","author":"Lim","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib97","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1248\/bpb.b23-00758","article-title":"Protective effects of coptis chinensis rhizome extract and its constituents (berberine, coptisine, and palmatine) against \u03b1-synuclein neurotoxicity in dopaminergic SH-SY5Y cells","volume":"47","author":"Lin","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2025.110555_bib98","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.fitote.2016.02.001","article-title":"Research progress on berberine with a special focus on its oral bioavailability","volume":"109","author":"Liu","year":"2016","journal-title":"Fitoterapia (Milano, 1934)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib100","article-title":"Berberine attenuates axonal transport impairment and axonopathy induced by calyculin a in N2a cells","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110555_bib101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1142\/S0192415X24500101","article-title":"Berberine alleviates ischemic brain injury by enhancing autophagic flux via facilitation of TFEB nuclear translocation","volume":"52","author":"Liu","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib102","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1124\/dmd.110.033936","article-title":"Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2025.110555_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100972","article-title":"Neuronal autophagy and mitophagy in Parkinson's disease","volume":"82","author":"Lizama","year":"2021","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-981-15-4272-5_2","article-title":"Autophagy and Parkinson?s disease","author":"Lu","year":"2020","journal-title":"Autophagy: biology and diseases: clinical science"},{"key":"10.1016\/j.neuropharm.2025.110555_bib105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/1547691X.2015.1058306","article-title":"Immunotoxicity induced in mice by subacute exposure to berberine","volume":"13","author":"Mahmoudi","year":"2016","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib106","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1074\/jbc.M111.262287","article-title":"Microtubule Affinity-regulating Kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: effects on mitochondrial transport","volume":"287","author":"Matenia","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110555_bib107","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbior.2017.05.005","article-title":"Regulation of GSK-3 activity by curcumin, berberine and resveratrol: potential effects on multiple diseases","volume":"65","author":"McCubrey","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.neuropharm.2025.110555_bib108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson's disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib109","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/ptr.6945","article-title":"Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia","volume":"35","author":"Mohammadlou","year":"2021","journal-title":"Phyther. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2174\/1386207324666210804122539","article-title":"Berberine in the treatment of neurodegenerative diseases and nanotechnology enabled targeted delivery","volume":"25","author":"Mohi-ud-din","year":"2021","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.neuropharm.2025.110555_bib111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.5530\/ijpi.13.4.089","article-title":"Protein phosphatase 2A activation for the treatment of alzheimer disease-promises and challenges","volume":"13","author":"Mondal","year":"2023","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.neuropharm.2025.110555_bib112","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1074\/jbc.M110.179390","article-title":"A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK\/PINK1: activation of AKT via MTORC2","volume":"286","author":"Murata","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110555_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13090881","article-title":"Environmental exposures and Parkinson's disease","volume":"13","author":"Nandipati","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.neuropharm.2025.110555_bib114","first-page":"1145","article-title":"Berberine chloride pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced neuronal insult in rat","volume":"14","author":"Negahdar","year":"2015","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105760","article-title":"The misfolding mystery: \u03b1-syn and the pathogenesis of Parkinson's disease","volume":"177","author":"Negi","year":"2024","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110555_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-024-00757-5","article-title":"Mechanisms of autophagy\u2013lysosome dysfunction in neurodegenerative diseases","author":"Nixon","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib117","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/toxins12110713","article-title":"Biological activity of berberine\u2014a summary update","volume":"12","author":"Och","year":"2020","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib118","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuropharm.2025.110555_bib119","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/acn3.337","article-title":"Dysregulation of protein phosphatase 2A in Parkinson disease and dementia with lewy bodies","volume":"3","author":"Park","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110555_bib120","article-title":"Development of an innovative berberine food-grade formulation with an ameliorated absorption: in vitro evidence confirmed by healthy human volunteers pharmacokinetic study","author":"Petrangolini","year":"2021","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9080647","article-title":"Mitochondrial dysfunction, oxidative stress, and neuroinflammation: intertwined roads to neurodegeneration","volume":"9","author":"Picca","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.neuropharm.2025.110555_bib122","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/nu14061220","article-title":"Vitamin D and Parkinson?s disease","volume":"14","author":"Pignolo","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2025.110555_bib123","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","article-title":"Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies","volume":"243","author":"Pirillo","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.neuropharm.2025.110555_bib124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncl.2019.12.002","article-title":"Pharmacologic treatment of motor symptoms associated with Parkinson disease","volume":"38","author":"Poewe","year":"2020","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuropharm.2025.110555_bib125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110555_bib126","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.2174\/1381612826666200523172334","article-title":"AMPK and its activator berberine in the treatment of neurodegenerative diseases","volume":"26","author":"Qin","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2025.110555_bib127","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1074\/jbc.M112.391680","article-title":"Phosphatase and tensin homolog (PTEN)-induced Putative Kinase 1 (PINK1)-dependent ubiquitination of endogenous parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons","volume":"288","author":"Rakovic","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110555_bib128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fphar.2020.00647","article-title":"Berberine improves glucose and lipid metabolism in HepG2 cells through AMPK\u03b11 activation","volume":"11","author":"Ren","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib129","first-page":"1688","article-title":"State of the science on brain insulin resistance and cognitive decline due to alzheimer's disease","volume":"15","author":"Rhea","year":"2024","journal-title":"Aging Dis"},{"key":"10.1016\/j.neuropharm.2025.110555_bib130","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.20892\/j.issn.2095-3941.2022.0330","article-title":"Targeting PP2A for cancer therapeutic modulation","volume":"19","author":"Ronk","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.neuropharm.2025.110555_bib131","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10495-022-01806-0","article-title":"Understanding the mechanistic roles of environmental heavy metal stressors in regulating ferroptosis: adding new paradigms to the links with diseases","volume":"28","author":"Sahoo","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.neuropharm.2025.110555_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115496","article-title":"GSK-3\u03b2: an exuberating neuroinflammatory mediator in Parkinson's disease","volume":"210","author":"Samim Khan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115496","article-title":"GSK-3\u03b2: an exuberating neuroinflammatory mediator in Parkinson's disease","volume":"210","author":"Samim Khan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib134","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.248187","article-title":"Protein phosphatase 2A \u2013 structure, function and role in neurodevelopmental disorders","volume":"134","author":"Sandal","year":"2021","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib135","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.4161\/cc.9.14.12180","article-title":"mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: a sensitized matter","volume":"9","author":"Santini","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neuropharm.2025.110555_bib136","article-title":"Inhibitory role of berberine, an isoquinoline alkaloid, on nlrp3 inflammasome activation for the treatment of inflammatory diseases","volume":"26","author":"Sarbadhikary","year":"2021","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib137","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neulet.2017.12.049","article-title":"Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson's disease","volume":"666","author":"Sekar","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110555_bib138","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1874467215666220509213122","article-title":"Berberine: is it a promising agent for mental disorders treatment? Curr","volume":"16","author":"Shayganfard","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib139","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/neup.12633","article-title":"Phosphatase and tensin homolog deletion enhances neurite outgrowth during neural stem cell differentiation","volume":"40","author":"Shen","year":"2020","journal-title":"Neuropathology (Kyoto, 1993)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2021.06.021","article-title":"Phosphatase and tensin homolog deleted on chromosome ten knockdown attenuates cognitive deficits by inhibiting microglia-mediated neuroinflammation in the Hippocampus in a mouse model of perioperative neurocognitive disorder","volume":"468","author":"Shen","year":"2021","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110555_bib141","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12272-013-0051-4","article-title":"Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"36","author":"Shin","year":"2013","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib142","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12272-013-0051-4","article-title":"Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"36","author":"Shin","year":"2013","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050796","article-title":"Therapeutic efficacies of berberine against neurological disorders: an update of pharmacological effects and mechanisms","volume":"11","author":"Shou","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2025.110555_bib144","doi-asserted-by":"crossref","DOI":"10.34172\/apb.2023.071","article-title":"Role of GSK-3\u03b2 inhibitors: new promises and opportunities for alzheimer's disease","author":"Shri","year":"2023","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2025.110555_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2018.00021","article-title":"Toxicological effects of berberine and sanguinarine","volume":"5","author":"Singh","year":"2018","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174202","article-title":"Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK\/GSK-3\u03b2\/PP2A pathway in Parkinson's disease","volume":"907","author":"Su","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1429050","article-title":"Neuroprotective effect and preparation methods of berberine","volume":"15","author":"Sunhe","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2020.100257","article-title":"Prescription pattern of anti-Parkinson\u2019s disease drugs in Japan based on a nationwide medical claims database","volume":"20","author":"Suzuki","year":"2020","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.neuropharm.2025.110555_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00679-2","article-title":"Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes","volume":"27","author":"Takahara","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12101883","article-title":"Neuroprotective properties of berberine: molecular mechanisms and clinical implications","volume":"12","author":"Tian","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.neuropharm.2025.110555_bib151","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/brainsci14060596","article-title":"Neuroprotective potentials of berberine in rotenone-induced Parkinson's disease-like motor symptoms in rats","volume":"14","author":"Tseng","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib152","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1007\/s12035-024-04003-z","article-title":"Therapeutic potential effect of glycogen synthase kinase 3 beta (GSK-3\u03b2) inhibitors in Parkinson disease: exploring an overlooked avenue","volume":"61","author":"Turkistani","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib153","article-title":"Berberine induces mitophagy through adenosine monophosphate-activated protein kinase and ameliorates mitochondrial dysfunction in PINK1 knockout mouse embryonic fibroblasts","volume":"25","author":"Um","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib154","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-025-01661-w","article-title":"Neuroprotective efficacy of berberine and caffeine against rotenone\u2010induced neuroinflammatory and oxidative disturbances associated with Parkinson's disease via inhibiting \u03b1-synuclein aggregation and boosting dopamine release","author":"Waheeb","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110555_bib155","doi-asserted-by":"crossref","first-page":"98312","DOI":"10.18632\/oncotarget.21203","article-title":"Berberine attenuated pro-inflammatory factors and protect against neuronal damage via triggering oligodendrocyte autophagy in spinal cord injury","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuropharm.2025.110555_bib156","article-title":"Inhibition of inflammation by berberine: molecular mechanism and network pharmacology analysis","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine (Stuttg.)"},{"key":"10.1016\/j.neuropharm.2025.110555_bib157","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s12035-020-01955-w","article-title":"Upregulation of AMPK ameliorates alzheimer's disease-like tau pathology and memory impairment","volume":"57","author":"Wang","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib158","article-title":"Treatment of Parkinson's disease in Zebrafish model with a berberine derivative capable of crossing blood brain barrier, targeting mitochondria, and convenient for bioimaging experiments","volume":"249","author":"Wang","year":"2021","journal-title":"Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib159","article-title":"Treatment of Parkinson's disease in Zebrafish model with a berberine derivative capable of crossing blood brain barrier, targeting mitochondria, and convenient for bioimaging experiments","volume":"249","author":"Wang","year":"2021","journal-title":"Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib162","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","article-title":"Incidence of Parkinson disease in north America","volume":"8","author":"Willis","year":"2022","journal-title":"npj Park. Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119824","article-title":"Functional effects of berberine in modulating mitochondrial dysfunction and inflammatory response in the respective amyloidogenic cells and activated microglial cells \u2013 in vitro models simulating Alzheimer's disease pathology","volume":"282","author":"Wong","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib164","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2022.05.025","article-title":"PINK1\/Parkin-mediated mitophagy in cardiovascular disease: from pathogenesis to novel therapy","volume":"361","author":"Wu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib166","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1389203720666190819142746","article-title":"AMPK: potential therapeutic target for Alzheimer's disease","volume":"21","author":"Yang","year":"2020","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib167","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.metabol.2008.01.013","article-title":"Efficacy of berberine in patients with type 2 diabetes mellitus","volume":"57","author":"Yin","year":"2008","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.neuropharm.2025.110555_bib168","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9923331","article-title":"The positive role and mechanism of herbal medicine in Parkinson's disease","author":"Yin","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2025.110555_bib169","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s12035-021-02670-w","article-title":"Cancerous inhibitor of protein phosphatase 2A (CIP2A): could it Be a promising biomarker and therapeutic target in Parkinson's disease?","volume":"59","author":"Yin","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-2011-101779","article-title":"Berberine attenuates calyculin A-induced cytotoxicity and tau hyperphosphorylation in HEK293 cells","volume":"24","author":"Yu","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neuropharm.2025.110555_bib171","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s12033-022-00651-5","article-title":"Berberine alleviates the damage, oxidative stress and mitochondrial dysfunction of PC12 cells induced by high glucose by activating the KEAP1\/nrf2\/ARE pathway","volume":"65","author":"Yuan","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107158","article-title":"Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine","volume":"128","author":"Zarrilli","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2025.110555_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.redox.2016.10.019","article-title":"Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K\/AKT\/Bcl-2 and Nrf2\/HO-1 pathways","volume":"11","author":"Zhang","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.neuropharm.2025.110555_bib174","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Review interaction between a\u03b2 and tau in the pathogenesis of alzheimer's disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2022.12607","article-title":"Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuropharm.2025.110555_bib176","first-page":"1197","article-title":"Pharmacologic preconditioning with berberine attenuating ischemia-induced apoptosis and promoting autophagy in neuron","volume":"8","author":"Zhang","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.neuropharm.2025.110555_bib177","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1556\/APhysiol.99.2012.3.8","article-title":"Hypoxia-inducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia\/ischemia","volume":"99","author":"Zhang","year":"2012","journal-title":"Acta Physiol. Hung."},{"key":"10.1016\/j.neuropharm.2025.110555_bib178","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41593-022-01239-7","article-title":"Post-translational modifications of soluble \u03b1-synuclein regulate the amplification of pathological \u03b1-synuclein","volume":"26","author":"Zhang","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110555_bib179","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10495-016-1234-5","article-title":"Berberine activates Nrf2 nuclear translocation and inhibits apoptosis induced by high glucose in renal tubular epithelial cells through a phosphatidylinositol 3-kinase\/Akt-dependent mechanism","volume":"21","author":"Zhang","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.neuropharm.2025.110555_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2006.10.025","article-title":"Berberine stimulates glucose transport through a mechanism distinct from insulin","author":"Zhou","year":"2007","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1016\/j.neuropharm.2025.110555_bib181","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neulet.2008.09.064","article-title":"Neuroprotective effects of berberine on stroke models in vitro and in vivo","volume":"447","author":"Zhou","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110555_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116715","article-title":"Berberine enhances autophagic flux to alleviate ischemic neuronal injury by facilitating N-ethylmaleimide-sensitive factor-mediated fusion of autophagosomes with lysosomes","volume":"232","author":"Zhuang","year":"2025","journal-title":"Biochem. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:26:58Z","timestamp":1779614818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825002618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":179,"alternative-id":["S0028390825002618"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110555","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Berberine's paradox in Neurodegeneration: Therapeutic promise and safety challenges in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110555"}}